A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease

Summary

Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection. This phase 2b/3 study will evaluate the efficacy and safety of zelicapavir compared with placebo in adults with RSV who are at high risk for severe disease. High-risk participants include those who are either ≥75 years of age or ≥18 years of age with COPD and/or CHF. Participants will be non-hospitalized adults who have up to 72 hours of respiratory tract infection symptoms and test positive for RSV.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• RSV

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2/3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Enanta Pharmaceuticals, Inc

Last updated on ClinicalTrials.gov

November 2, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites